Highest-materiality recent filing
Regenerex Pharma sues former CFO's Optimize Health for overbilling, breach of contract
Filed lawsuit against Optimize Health Partners (owned by ex-CFO Kenneth Perry) for breach of software license agreement.
Regenerex sues former CFO Perry for alleged $55K overpayments, $37K overcharges, stock theft
Complaint filed June 5, 2026, in Smith County Chancery Court (Case No. 2026-CV-8813).
Regenerex Pharma terminates CFO Kenneth Perry for cause; appoints Don E. Ray as interim CFO
Kenneth Perry placed on administrative suspension with pay on March 31, 2026.
Regenerex Pharma suspends CFO Kenneth Perry; appoints Don E. Ray as interim CFO
CFO Kenneth Perry placed on administrative suspension leave with pay, effective March 31, 2026, due to concerns over compliance, financial oversight, governance, and internal controls.
Regenerex Pharma changes fiscal year end from March 31 to December 31
Board approved fiscal year change effective September 22, 2025.
Exclusive worldwide rights to Holista's ovine collagen for wound care; initial focus on U.S. market.
Regenerex Pharma enters licensing deal with Holista for ovine collagen wound care
Exclusive rights to use Holista's ovine collagen in wound care and distribution in USA.
Regenerex Pharma appoints Kenneth Perry as CFO; Brent Wilson resigns effective March 31, 2025
Kenneth W. Perry appointed CFO effective March 31, 2025; 39 years of healthcare finance experience.
RegeneRx Pharma announces CFO resignation and appointments of new CFO, Secretary, and board member
Deborah Pilant resigned as CFO, Secretary/Treasurer, and board director effective Dec 6, 2024, due to retirement.
Regenerex Pharma announces 95% wound closure rate and Q4 2023 manufacturing plans
Products Xcellderma and Accelerex target chronic wounds via proprietary QBx ingredient.
Irene Getty resigned as CFO, Bruce Sellars resigned from board, Byron Striloff resigned as officer, all effective Aug 25, 2022.
RegeneRex Pharma appoints Troy Thuet as COO; Dr. Lee Ori becomes Chief R&D Officer
Troy Thuet appointed COO effective Jan 14, 2022; over 15 years of managerial and executive experience.
Peptide Technologies names Gregory Pilant CEO/Chairman, Deborah Pilant Secretary/Treasurer
Gregory P. Pilant appointed CEO and Chairman of the Board effective Nov 16, 2021; Deborah L. Pilant appointed Secretary/Treasurer.
Peptide Technologies acquires wound healing IP for 150M shares and $10M deferred cash
Acquired Wound Healing Technology Platform from Gregory P. Pilant and Deborah L. Pilant for 150M restricted common shares and $10M deferred cash.
As of June 5, 2026, the Company has commenced legal proceedings against its former Chief Financial Officer, Kenneth W. Perry (the "Former CFO"), in the matter of Regenerex Pharma, Inc. v. Kenneth W. Perry , Smith County Chancery Court, Case No. 2026-CV-8813.
In connection with the foregoing, on April 1, 2026, the Board appointed Don E. Ray to serve as Interim Chief Financial Officer of the Company.
Following the Committee’s review and recommendation, the Independent Board of Directors approved the termination of Mr. Perry’s employment for Cause, with notice of such termination delivered on May 2, 2026.
Effective March 31, 2025, Mr. Brent Wilson resigned his position as Chief Financial Officer of the Company due to personal reasons.
Effective March 31, 2025, Mr. Kenneth W. Perry has been appointed to serve as Chief Financial Officer for the company
Effective August 25, 2022, Irene Getty tendered her letter of resignation to the Company resigning from her positions as Chief Financial Officer
Effective August 25, 2022, Bruce Sellars tendered his letter of resignation to the Company resigning from his position as a member of the Board of Directors.
Effective August 25, 2022, Deborah L. Pilant has been appointed to serve as Chief Financial Officer of the Company.
Effective August 25, 2022, Byron Striloff tendered his letter of resignation to the Company resigning from his position as an Officer of the Company.
Effective August 25, 2022, Dr Lee Ori has been elected/appointed to the Board of Directors of the Company.
He is replacing Dr. Lee Ori who has been appointed as Chief R & D Officer of the Company for the coming year.
Effective January 14, 2022, Mr. Troy Thuet has been appointed to serve as Chief Operating Officer of the Company for the coming year.
Max materiality 0.75 · Median 0.65 · Most common event leadership